Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
Phase 2/3
150
about 9 months
40–85
1 site in IL
What this study is about
Researchers are testing whether alternative therapies, such as metformin alone or with rapamycin and low-dose naltrexone, can help maintain weight loss after stopping GLP-1 medications. The trial will compare different groups of participants who either use these alternatives or do not to see if they experience less weight regain over six months post-cessation compared to those without any alternative medication.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Metformin
- 2.Take Naltrexone
- 3.Take Rapamycin
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
metformin (Biguanide antidiabetic; reduces liver glucose production and improves insulin sensitivity), naltrexone, sirolimus, ascorbic acid (vit C)
oral, injection, intramuscular
Secondary: Evaluate the effectiveness of metformin + LDN on mood-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + LDN on physical health-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + LDN on tolerability of treatment in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + rapamycin on mood-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + rapamycin on physical health-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + rapamycin on tolerability of treatment in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin on mood-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin on physical health-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)